Rhinopharynx irrigations and mouthwash with dissolved mupirocin in treatment of MRSA throat colonization - proof-of-concept study.

BACKGROUND: To prevent transmission of, and infection with, meticillin-resistant Staphylococcus aureus (MRSA), eradication treatment of colonized individuals is recommended. Throat colonization is a well-known risk factor for eradication failure. Staphylococcus aureus throat colonization is associated with colonization of the rhinopharynx, but in the currently recommended Danish MRSA eradication strategies, rhinopharynx colonization is not directly targeted. Rhinopharynx colonization could therefore be an important risk factor for prolonged MRSA throat carriage. AIM: To determine whether irrigation and wash of the rhinopharynx and mouth with dissolved mupirocin is a feasible and potentially efficacious supplementary strategy against treatment-resistant MRSA throat carriage. METHODS: The patient study was an open, non-blinded, trial including 20 treatment-resistant MRSA throat carriers. In the study, the patients received a supplementary treatment besides the standard treatment according to the Danish MRSA eradication strategy. The supplementary treatment consisted of rhinopharyngeal irrigation and mouth-gurgling twice a day for 14 days with a mupirocin ointment (22 g 2% ointment per litre of isotonic sterile saline solution) in a 37°C solution. FINDINGS: Eighteen patients (90%) complied with the treatment protocol and none ex-perienced any major adverse events. Out of the 18 patients who finished the study per protocol, 15 (83%) and seven (39%) patients had negative MRSA sampling results one and six months after end of treatment, respectively. CONCLUSION: This study demonstrates the feasibility and clinical potential of also targeting the rhinopharynx and oropharynx in non-systemic throat MRSA eradication strategies.

Danish experience of meticillin-resistant Staphylococcus aureus eradication with emphasis on nose-throat colonization and supplementary systemic antibiotic treatment.

This study aimed to evaluate the Danish Board of Health's guidance for treating the carriage of meticillin-resistant Staphylococcus aureus (MRSA), focusing on nose-throat carriage and use of supplementary systemic antibiotics. The results of MRSA eradication treatment among 358 patients were analysed, focusing on those with nose (N=58) or throat (N=183) MRSA colonization. The Danish guidance for MRSA treatment was found to be more successful in patients with nose colonization (66%) compared with throat colonization (41%), despite the fact that the cumulative eradication rates were equal after three treatment cycles (71% vs 73%). This study found that supplementation of colonization treatment with systemic antibiotics does not have a positive effect.

Epidemiology of methicillin-resistant Staphylococcus aureus carrying the novel mecC gene in Denmark corroborates a zoonotic reservoir with transmission to humans.

Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of healthcare-associated (HA), community-associated (CA) and livestock-associated (LA) infections. Recently, the discovery of human and bovine MRSA isolates carrying a new mecA gene homologue, mecA(LGA251) (now designated mecC), has caused concern because they are not detected by conventional, confirmatory tests for MRSA. Very little is known about their frequency, epidemiology and possible transmission between livestock and humans. In this study, the epidemiology of the mecC isolates in Denmark was investigated by screening the national collections of MRSA cases (from 1988 onwards) and S. aureus bacteraemia cases (from 1958 onwards). Isolates carrying mecC were only recovered infrequently before 2003 (n = 2) but now seem to be increasing, with 110 cases in 2003-2011. Clinical data on mecC-carrying MRSA demonstrated that mecC-MRSA were primarily community-acquired (CA-MRSA) and affected persons typically living in rural areas, being older than other CA-MRSA patients. Among 22 cases in Region Zealand, four reported contact with cattle and sheep. Two of these persons lived on farms with livestock positive for mecC-carrying MRSA, sharing spa type (t843), MLVA (MT429) and PFGE pattern with the human isolates. These observations indicate that mecC-carrying MRSA can be exchanged between humans and ruminants.

No effect of low power laser in lateral epicondylitis.

Thirty-six patients with lateral epicondylitis of the elbow (19 women, 17 men, median age 48 yrs) were treated either with active laser or placebo, 18 patients in each group. The active laser was a GA-AL-AS 30 mW/830 nm low power laser (LPL). The study design was double blind and randomized. The treatment session consisted of eight treatments, two per week. Patients were irradiated on tender points on the lateral epicondyle and in the forearm extensors. Output power was 3,6 J/point. A follow up was performed by telephone, 10 weeks after the last treatment. No difference between laser and placebo was found on lateral elbow pain (Mann Whitney test, 95% confidence limits). We conclude that low power laser offers no advantage over placebo in the treatment of musculoskeletal pain as lateral epicondylitis. Further studies with low power laser treatment of musculoskeletal pain seem useless.